by The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) inhibitors are a class of drugs that help the immune system fight cancer cells. They work by blocking signals between PD-1 and PD-L1, allowing T cells to recognize and destroy cancer cells in the body. Some key cancers where these drugs are used include melanoma, lung cancer, kidney cancer, and various hematological malignancies. Their effectiveness against certain cancers and ability to improve survival rates compared to conventional chemotherapies have made them an essential part of treatment regimens.
Market key trends:
The rising incidence of cancer globally is a major driver for the PD-1 and PD-L1 inhibitor market. According to WHO, cancer burden rose to 19.3 million new cases and 10.0 million cancer deaths in 2020. Furthermore, approvals of these drugs for additional cancer types and in earlier lines of therapy are expanding their scope of applications. Drug combinations of PD-1/PD-L1 inhibitors with other immunotherapies are also a growing trend, improving clinical outcomes. Growing awareness about immunotherapies and their benefits compared to other treatments further supports market growth. However, high costs of these drugs continue to hinder broader adoption in low and middle-income countries.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the PD-1 and PD-L1 Inhibitor Market requires extensive R&D and clinical trials for new drug development which requires large investments.
Bargaining power of buyers: The bargaining power of buyers is high due to presence of many established pharmaceutical companies offering generic versions of drugs.
Bargaining power of suppliers: The bargaining power of suppliers is low since raw materials used in manufacturing PD-1 and PD-L1 Inhibitors are commodity products and available with many suppliers.
Threat of new substitutes: The threat of new substitutes is low as PD-1 and PD-L1 Inhibitors have limited substitutes for cancer treatment currently.
Competitive rivalry: The competitive rivalry is high due to many global players offering similar drugs.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Share is expected to witness high growth, exhibiting CAGR of 14.% over the forecast period, due to increasing incidence of cancer globally. The market size for 2023 is estimated to be US$ 39.83 Bn.
North America is expected to dominate the global PD-1 and PD-L1 Inhibitor Market owing to increasing healthcare expenditure and high adoption of PD-1 and PD-L1 Inhibitors in the region for cancer treatment. Asia Pacific is anticipated to exhibit fastest growth during the forecast period driven by rising focus of key players towards emerging Asian markets and improving healthcare infrastructure in the region.
Key players operating in the PD-1 and PD-L1 Inhibitor Market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc. Major players are focusing on developing innovative combination therapies to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals.
